4篇
您的检索式：作者名="Nitin Arora"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Modified non-recursive algorithm for reconstructing a binary tree 显示文摘 | Nitin Arora Vivek Kumar Tamta Suresh Kumar | 2012 | International Journal of Computer Applications2012，43，10： | 1 |
| 2 | A comparison between fibrin sealant and sutures for attaching conjunctival autograft after pterygium excision显示文摘 | Nitin Vichare Tarun Choudhary Priyanka Arora | 2013 | Medical Journal Armed Forces India2013，，2： | 1 |
| 3 | Natural polysaccharides for ulcerative colitis: A general overview显示文摘Ulcerative colitis is a colonic disease characterized by the disruption of the mucosal epithelial layer and inflammation. For the treatment of this disease, various chemotherapeutic agents are available.However, the toxicities associated with chemotherapeutics greatly hamper treatment. Polysaccharide from natural resources is emerging as a potentially therapeutic substance with comparative minimum adverse effects. In this article, we are discussing polysaccharide from diverse sources(plants, edible mushrooms,and algae) which are being used in the treatment of ulcerative colitis. These polysaccharides exert their therapeutic action on ulcerative colitis through several mechanisms, including suppression of inflammatory cascades NF-κB, MAPK, IL-6/JAK2/STAT3,preventing the release of certain inflammatory mediators, modulating the intestinal microbiome, maintaining the integrity of intestinal barriers, and regulating the certain inflammatory markers. The present review compiles the role of different polysaccharides being used successfully in the management/treatment of ulcerative colitis.Special emphasis was given to explaining the biomolecular pathway. | Akshita Arora Nitin Sharma Dipti Kakkar | 2023 | Asian Pacific Journal of Tropical Biomedicine2023，13，5： | 0 |
| 4 | Vaccinations in kidney transplant recipients: Clearing the muddy waters显示文摘Vaccine preventable diseases account for a significant proportion of morbidity and mortality in transplant recipients and cause adverse outcomes to the patient and allograft. Patients should be screened for vaccination history at the time of pre-transplant evaluation and vaccinated at least four weeks prior to transplantation. For non-immune patients, dead-vaccines can be administered starting at six months post-transplant. Live attenuated vaccines are contraindicated after transplant due to concern for infectious complications from the vaccine and every effort should be made to vaccinate prior to transplant.Since transplant recipients are on life-long immunosuppression, these patients may have lower rates of serological conversion, lower mean antibody titers and waning of protective immunity over shorter period as compared to general population. Recommendations regarding booster dose in kidney transplant recipients with sub-optimal serological response are lacking. Travel plans should be part of routine post-transplant assessment and pre-travel vaccines and counseling should be provided. More studies are needed on vaccination schedules, serological response, need for booster doses and safety of live attenuated vaccines in this special population. | Swati Arora Gretchen Kipp Nitin Bhanot Kalathil K Sureshkumar | 2019 | World Journal of Transplantation2019，9，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员